Published in Neurology on December 26, 2012
Minocycline for HIV+ Cognitive Impairment in Uganda | NCT00855062
Monocyte/macrophages and their role in HIV neuropathogenesis. Immunol Rev (2013) 1.31
A systematic review of the screening accuracy of the HIV Dementia Scale and International HIV Dementia Scale. PLoS One (2013) 0.97
Neurocognitive function in HIV-infected patients: comparison of two methods to define impairment. PLoS One (2014) 0.86
Biotic acts of antibiotics. Front Microbiol (2013) 0.86
Adjuvant therapies for HIV-associated neurocognitive disorders. Ann Clin Transl Neurol (2014) 0.85
Elevated brain monoamine oxidase activity in SIV- and HIV-associated neurological disease. J Infect Dis (2014) 0.84
Immune activation in the central nervous system throughout the course of HIV infection. Curr Opin HIV AIDS (2016) 0.82
Cognitive remission: a novel objective for the treatment of major depression? BMC Med (2016) 0.80
The recombinant vaccinia virus gene product, B18R, neutralizes interferon alpha and alleviates histopathological complications in an HIV encephalitis mouse model. J Interferon Cytokine Res (2014) 0.80
Attenuation of pathogenic immune responses during infection with human and simian immunodeficiency virus (HIV/SIV) by the tetracycline derivative minocycline. PLoS One (2014) 0.77
Defining cognitive impairment in people-living-with-HIV: the POPPY study. BMC Infect Dis (2016) 0.75
Direct Targeting of Macrophages With Methylglyoxal-Bis-Guanylhydrazone Decreases SIV-Associated Cardiovascular Inflammation and Pathology. J Acquir Immune Defic Syndr (2017) 0.75
Novel Antiplatelet Activity of Minocycline Involves Inhibition of MLK3-p38 Mitogen Activated Protein Kinase Axis. PLoS One (2016) 0.75
HIV-1-associated neurocognitive disorder: epidemiology, pathogenesis, diagnosis, and treatment. J Neurol (2017) 0.75
Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol (2007) 5.46
The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS (2007) 5.18
The International HIV Dementia Scale: a new rapid screening test for HIV dementia. AIDS (2005) 4.48
Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc Natl Acad Sci U S A (1998) 4.14
Minocycline treatment in acute stroke: an open-label, evaluator-blinded study. Neurology (2007) 3.82
Frequency of and risk factors for HIV dementia in an HIV clinic in sub-Saharan Africa. Neurology (2007) 3.14
Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc Natl Acad Sci U S A (2001) 2.95
Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS (2009) 2.88
The promise of minocycline in neurology. Lancet Neurol (2004) 2.06
Neuroprotective and anti-human immunodeficiency virus activity of minocycline. JAMA (2005) 1.80
Depression symptoms and cognitive function among individuals with advanced HIV infection initiating HAART in Uganda. BMC Psychiatry (2010) 1.73
Minocycline attenuates HIV infection and reactivation by suppressing cellular activation in human CD4+ T cells. J Infect Dis (2010) 1.70
Antiretroviral therapy improves cognitive impairment in HIV+ individuals in sub-Saharan Africa. Neurology (2006) 1.56
Combination antiretroviral therapy improves psychomotor speed performance in HIV-seropositive homosexual men. Multicenter AIDS Cohort Study (MACS). Neurology (1999) 1.46
Suppression of inflammatory neurotoxins by highly active antiretroviral therapy in human immunodeficiency virus-associated dementia. J Infect Dis (1998) 1.46
Minocycline: A review of its antibacterial and pharmacokinetic properties and therapeutic use. Drugs (1975) 1.38
Pattern of neuropsychological performance among HIV positive patients in Uganda. BMC Neurol (2007) 1.35
The tetracycline derivative minocycline differentially affects cytokine production by monocytes and T lymphocytes. Antimicrob Agents Chemother (1996) 1.18
Minocycline blocks nitric oxide-induced neurotoxicity by inhibition p38 MAP kinase in rat cerebellar granule neurons. Neurosci Lett (2001) 1.17
Pilot study of minocycline in relapsing-remitting multiple sclerosis. Can J Neurol Sci (2008) 1.09
Tuberculous meningitis in HIV-infected individuals. Curr HIV/AIDS Rep (2009) 1.08
A novel action of minocycline: inhibition of human immunodeficiency virus type 1 infection in microglia. J Neurovirol (2004) 1.07
Minocycline treatment for HIV-associated cognitive impairment: results from a randomized trial. Neurology (2011) 1.07
Screening for hepatitis C among HIV positive patients at Mulago hospital in Uganda. Afr Health Sci (2009) 1.04
Hepatitis C infection, Cognition, and inflammation in an Egyptian sample. J Med Virol (2011) 0.81
Nutritional Contributions to the CNS Pathophysiology of HIV-1 Infection and Implications for Treatment. CNS Spectr (2000) 0.79
Chapter 12- Brain as an HIV sequestered site: Use of nanoparticles as a therapeutic option. Prog Brain Res (2009) 0.79
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med (2012) 27.84
HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol (2010) 7.56
Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med (2006) 5.20
Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS (2004) 4.64
The International HIV Dementia Scale: a new rapid screening test for HIV dementia. AIDS (2005) 4.48
HIV prevention transformed: the new prevention research agenda. Lancet (2011) 4.23
Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial. Lancet (2010) 4.23
The prospective course of rapid-cycling bipolar disorder: findings from the STEP-BD. Am J Psychiatry (2008) 3.82
Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy. J Acquir Immune Defic Syndr (2007) 3.78
Characteristics of HIV-1 discordant couples enrolled in a trial of HSV-2 suppression to reduce HIV-1 transmission: the partners study. PLoS One (2009) 3.66
Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study. Clin Infect Dis (2005) 3.47
Long-term implications of early onset in bipolar disorder: data from the first 1000 participants in the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biol Psychiatry (2004) 3.43
Characteristics of HIV-1 serodiscordant couples enrolled in a clinical trial of antiretroviral pre-exposure prophylaxis for HIV-1 prevention. PLoS One (2011) 3.27
A single amino acid residue can determine the sensitivity of SERCAs to artemisinins. Nat Struct Mol Biol (2005) 3.18
PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section. Neurology (2013) 3.02
Response to antiretroviral therapy in HIV-infected patients attending a public, urban clinic in Kampala, Uganda. Clin Infect Dis (2005) 3.00
Human immunodeficiency virus-associated neurocognitive disorders: Mind the gap. Ann Neurol (2010) 2.96
HIV and aging: state of knowledge and areas of critical need for research. A report to the NIH Office of AIDS Research by the HIV and Aging Working Group. J Acquir Immune Defic Syndr (2012) 2.95
Human immunodeficiency virus-associated dementia: an evolving disease. J Neurovirol (2003) 2.93
Continued high prevalence and adverse clinical impact of human immunodeficiency virus-associated sensory neuropathy in the era of combination antiretroviral therapy: the CHARTER Study. Arch Neurol (2010) 2.91
Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS (2009) 2.88
A call to action for comprehensive HIV services for men who have sex with men. Lancet (2012) 2.70
Progressive multifocal leukoencephalopathy and other forms of JC virus disease. Nat Rev Neurol (2010) 2.48
Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East Africa. PLoS Med (2013) 2.44
Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study. J Infect Dis (2005) 2.43
The etiology of urinary tract infection: traditional and emerging pathogens. Dis Mon (2003) 2.39
Should active recruitment of health workers from sub-Saharan Africa be viewed as a crime? Lancet (2008) 2.31
Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals. Ann Intern Med (2005) 2.26
Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol (2011) 2.19
Sexual behaviour of heterosexual men and women receiving antiretroviral pre-exposure prophylaxis for HIV prevention: a longitudinal analysis. Lancet Infect Dis (2013) 2.18
Examining the evidence on the causal effect of HAART on transmission of HIV using the Bradford Hill criteria. AIDS (2013) 2.17
Severe mental illness at ART initiation is associated with worse retention in care among HIV-infected Ugandan adults. Trop Med Int Health (2012) 2.08
Acceptance of routine testing for HIV among adult patients at the medical emergency unit at a national referral hospital in Kampala, Uganda. AIDS Behav (2006) 2.08
Prevalence, incidence and predictors of severe anaemia with zidovudine-containing regimens in African adults with HIV infection within the DART trial. Antivir Ther (2006) 2.02
Depression, alcohol use and adherence to antiretroviral therapy in sub-Saharan Africa: a systematic review. AIDS Behav (2012) 2.01
An evaluation of neurocognitive status and markers of immune activation as predictors of time to death in advanced HIV infection. Arch Neurol (2007) 1.94
Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort. AIDS (2011) 1.90
Phenomenology of rapid-cycling bipolar disorder: data from the first 500 participants in the Systematic Treatment Enhancement Program. Am J Psychiatry (2004) 1.86
Foundations for self-awareness: An exploration through autism. Monogr Soc Res Child Dev (2006) 1.84
HIV counseling and testing practices at an urban hospital in Kampala, Uganda. AIDS Behav (2006) 1.83
Dendritic spine injury induced by the 8-hydroxy metabolite of efavirenz. J Pharmacol Exp Ther (2012) 1.79
Attenuated central nervous system infection in advanced HIV/AIDS with combination antiretroviral therapy. Arch Neurol (2004) 1.79
Lowest ever CD4 lymphocyte count (CD4 nadir) as a predictor of current cognitive and neurological status in human immunodeficiency virus type 1 infection--The Hawaii Aging with HIV Cohort. J Neurovirol (2006) 1.76
Depression symptoms and cognitive function among individuals with advanced HIV infection initiating HAART in Uganda. BMC Psychiatry (2010) 1.73
The evolving face of human immunodeficiency virus-related progressive multifocal leukoencephalopathy: defining a consensus terminology. J Neurovirol (2003) 1.70
Using mobile phones to improve clinic attendance amongst an antiretroviral treatment cohort in rural Uganda: a cross-sectional and prospective study. AIDS Behav (2010) 1.69
Linkage to HIV care and survival following inpatient HIV counseling and testing. AIDS Behav (2011) 1.66
Increased human immunodeficiency virus type 1 (HIV-1) env compartmentalization in the presence of HIV-1-associated dementia. J Virol (2005) 1.65
HIV subtype D is associated with dementia, compared with subtype A, in immunosuppressed individuals at risk of cognitive impairment in Kampala, Uganda. Clin Infect Dis (2009) 1.64
Treatment of progressive multifocal leukoencephalopathy associated with natalizumab. N Engl J Med (2009) 1.63
Primary mania versus HIV-related secondary mania in Uganda. Am J Psychiatry (2006) 1.62
A lipid storage-like disorder contributes to cognitive decline in HIV-infected subjects. Neurology (2013) 1.62
Evolution of HIV dementia with HIV infection. Int Rev Psychiatry (2008) 1.58
Clinical factors related to brain structure in HIV: the CHARTER study. J Neurovirol (2011) 1.57
Response to a selective serotonin reuptake inhibitor (citalopram) in major depressive disorder with melancholic features: a STAR*D report. J Clin Psychiatry (2008) 1.57
Clinical validation of the NeuroScreen. J Neurovirol (2005) 1.57
Peripheral neuropathy in HIV: prevalence and risk factors. AIDS (2011) 1.53
Subcortical brain atrophy persists even in HAART-regulated HIV disease. Brain Imaging Behav (2011) 1.53
Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants. Pharmacogenet Genomics (2012) 1.52
Frequency and phenotype of JC virus-specific CD8+ T lymphocytes in the peripheral blood of patients with progressive multifocal leukoencephalopathy. J Virol (2007) 1.52
Case-control analyses of the impact of pharmacotherapy on prospectively observed suicide attempts and completed suicides in bipolar disorder: findings from STEP-BD. J Clin Psychiatry (2008) 1.51
Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer. J Clin Oncol (2006) 1.51
Multidisciplinary quality improvement initiative to reduce ventilator-associated tracheobronchitis in the PICU. Pediatr Crit Care Med (2013) 1.51
Reducing the burden of HIV/AIDS in infants: the contribution of improved diagnostics. Nature (2006) 1.48
Low atazanavir concentrations in cerebrospinal fluid. AIDS (2009) 1.45
Pivotal results of the Medtronic Vascular Talent Thoracic Stent Graft System: the VALOR trial. J Vasc Surg (2008) 1.44
Baseline predictors of serious adverse events at one year among patients with bipolar disorder in STEP-BD. Psychiatr Serv (2005) 1.43
Cerebrospinal fluid and neuroimaging biomarker abnormalities suggest early neurological injury in a subset of individuals during primary HIV infection. J Infect Dis (2013) 1.42
Cross-sectional characterization of HIV-1 env compartmentalization in cerebrospinal fluid over the full disease course. AIDS (2009) 1.40
Mitochondrial haplogroups and peripheral neuropathy during antiretroviral therapy: an adult AIDS clinical trials group study. AIDS (2005) 1.39
Developing independent investigators for clinical research relevant for Africa. Health Res Policy Syst (2011) 1.39
Patterns of individual and population-level adherence to antiretroviral therapy and risk factors for poor adherence in the first year of the DART trial in Uganda and Zimbabwe. J Acquir Immune Defic Syndr (2008) 1.37
Male circumcision and risk of male-to-female HIV-1 transmission: a multinational prospective study in African HIV-1-serodiscordant couples. AIDS (2010) 1.37
Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol (2007) 1.36